» Articles » PMID: 17998146

Activation of the ERK and AKT Signalling Pathway Predicts Poor Prognosis in Hepatocellular Carcinoma and ERK Activation in Cancer Tissue is Associated with Hepatitis C Virus Infection

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2007 Nov 14
PMID 17998146
Citations 130
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: The aim of the study was to determine the prognostic relevance of AKT and extracellular regulated kinases (ERK1/2), which are implied in the regulation of cell proliferation and apoptosis, in hepatocellular carcinoma (HCC).

Methods: This study comprised a series of 208 patients incorporating HCCs treated either by surgical resection (n = 109) or liver transplantation (n = 99). Immunohistochemically demonstrated phospho-ERK1/2 (pERK1/2) and phospho-AKT (pAKT) was correlated with a series of clinico-pathologically relevant parameters (EGFR, Cyclin-D1, HCV/HBV infection, liver cirrhosis, chronic alcohol abuse), proliferative activity, and apoptosis.

Results: Activation of ERK1/2 correlated statistically with the presence of HCV infection. pERK1/2 (P < 0.001) and pAKT (P = 0.052) expression showed a significant correlation with a decreased overall survival (OS). In multivariate Cox regression analysis pERK1/2 was identified as an independent prognostic parameter in HCC (P = 0.026).

Conclusions: Activation of ERK1/2 in HCC cancer indicates aggressive tumour behaviour and constitutes an independent prognostic factor. Furthermore our data confirm that HCV infection activates the ERK pathway and thereby might contribute to HCC carcinogenesis. Immunohistochemical determination of pERK1/2 status can thus be proposed as a promising candidate for the identification of high risk patients who may benefit from new anticancer drugs targeting the ERK-pathway.

Citing Articles

Microcystin-LR activates serine/threonine kinases and alters the phosphoproteome in human HepaRG cells.

Ikumawoyi V, Lynch K, Iverson D, Ridge Call M, Yue G, Prasad B Toxicon. 2024; 249:108072.

PMID: 39154757 PMC: 11402562. DOI: 10.1016/j.toxicon.2024.108072.


Erk Inhibition as a Promising Therapeutic Strategy for High IL-8-Secreting and Low SPTAN1-Expressing Colorectal Cancer.

Meier C, La Rocca G, Nawrot V, Fisslthaler B, Overby S, Hourfar K Int J Mol Sci. 2024; 25(11).

PMID: 38891846 PMC: 11172072. DOI: 10.3390/ijms25115658.


Unraveling the Janus-Faced Role of Autophagy in Hepatocellular Carcinoma: Implications for Therapeutic Interventions.

Nguyen T, Nguyen T, Ngoc D, You T, Park M, Lee C Int J Mol Sci. 2023; 24(22).

PMID: 38003445 PMC: 10671265. DOI: 10.3390/ijms242216255.


p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer.

de Kort W, de Ruiter E, Haakma W, Driehuis E, Devriese L, van Es R Head Neck Pathol. 2023; 17(3):697-707.

PMID: 37486536 PMC: 10514008. DOI: 10.1007/s12105-023-01576-4.


Arsenic and Tau Phosphorylation: a Mechanistic Review.

Ariafar S, Makhdoomi S, Mohammadi M Biol Trace Elem Res. 2023; 201(12):5708-5720.

PMID: 37211576 DOI: 10.1007/s12011-023-03634-y.